ChromaDex (CDXC)’s Stock Insider Transaction – Mark Friedman Acquires 3,000 Shares; Citi Trends (CTRN) Has 1.52 Sentiment

ChromaDex Corporation (NASDAQ:CDXC) Logo

Citi Trends Inc (CTRN) investors sentiment decreased to 1.52 in Q4 2017. It’s down -0.09, from 1.61 in 2017Q3. The ratio fall, as 64 hedge funds increased and started new positions, while 42 decreased and sold equity positions in Citi Trends Inc. The hedge funds in our database now hold: 11.83 million shares, up from 11.70 million shares in 2017Q3. Also, the number of hedge funds holding Citi Trends Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 35 Increased: 30 New Position: 34.

Garnet Equity Capital Holdings Inc. holds 5.53% of its portfolio in Citi Trends, Inc. for 261,000 shares. Awm Investment Company Inc. owns 430,000 shares or 2.21% of their US portfolio. Moreover, Kestrel Investment Management Corp has 1.78% invested in the company for 192,975 shares. The New York-based Paradigm Capital Management Inc Ny has invested 1.43% in the stock. Northpointe Capital Llc, a Michigan-based fund reported 159,610 shares.

Since January 1, 0001, it had 0 insider purchases, and 3 insider sales for $636,612 activity.

The stock increased 0.33% or $0.1 during the last trading session, reaching $30.54. About 51,035 shares traded. Citi Trends, Inc. (CTRN) has risen 78.30% since May 18, 2017 and is uptrending. It has outperformed by 66.75% the S&P500.

More news for Citi Trends, Inc. (NASDAQ:CTRN) were recently published by:, which released: “Detailed Research: Economic Perspectives on Xylem, SEACOR, Acxiom, Stepan, Citi Trends, and Saul Centers …” on May 18, 2018.‘s article titled: “Citi Trends Sets Date for First Quarter 2018 Earnings Release and Conference Call” and published on May 04, 2018 is yet another important article.

Citi Trends, Inc. operates as an off-price retailer of urban fashion apparel and accessories. The company has market cap of $419.99 million. The firm offers apparel comprising fashion sportswear for men, women, and children, as well as offerings for newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and decorative home products, functional home products, beauty products, books, toys, and electronic accessories. It has a 29.65 P/E ratio. It also offers its products through the Internet.

The GENERAL COUNSEL of Chromadex Corp, Mark Friedman has made an unexpected purchase in the ‘s company that is worth $10,800 US Dollars. As stated in the (SEC) electronic report filed on May 17, 2018, Mark bought 3,000 shares which is calculated with stock price per share of $3.6. Mark now has rights to 3,000 shares accounting for 0.01% of the Company’s market cap

More notable recent ChromaDex Corporation (NASDAQ:CDXC) news were published by: which released: “ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes” on May 01, 2018, also with their article: “ChromaDex Corporation Reports First Quarter 2018 Financial Results” published on May 10, 2018, published: “ChromaDex’s (CDXC) CEO Frank Jaksch on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018. More interesting news about ChromaDex Corporation (NASDAQ:CDXC) were released by: and their article: “ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board” published on May 14, 2018 as well as‘s news article titled: “Midday Stock Roundup” with publication date: May 14, 2018.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company has market cap of $204.10 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It currently has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

Analysts await ChromaDex Corporation (NASDAQ:CDXC) to report earnings on August, 9. They expect $-0.03 earnings per share, up 40.00% or $0.02 from last year’s $-0.05 per share. After $-0.15 actual earnings per share reported by ChromaDex Corporation for the previous quarter, Wall Street now forecasts -80.00% EPS growth.

The stock increased 5.98% or $0.21 during the last trading session, reaching $3.72. About 244,140 shares traded. ChromaDex Corporation (NASDAQ:CDXC) has risen 63.20% since May 18, 2017 and is uptrending. It has outperformed by 51.65% the S&P500.

Citi Trends, Inc. (NASDAQ:CTRN) Institutional Positions Chart